It still irks me that they are selecting 4 endpoints out of the 9 they tested when presenting the data. They had the opportunity to use the same or similar endpoint(s).
"Neurotech examined a large number of anchors (sub-domains) to further understand which important sub-domains benefits NTI164 improved that could be targeted in registration-directed trials. In late-stage clinical trials, typically 2-3 subdomains are typically examined for CGI-I"
This statement doesn't track IMO. I think they will have issues with a registrational trial with those sub domains.
It still irks me that they are selecting 4 endpoints out of the...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NTI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
-0.001(1.82%) |
Mkt cap ! $55.86M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.5¢ | 5.3¢ | $44.13K | 814.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 3289722 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.5¢ | 253965 | 2 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| NTI (ASX) Chart |